Suriclone | RP-31264 | CAS#53813-83-5 | GABA-A Receptor Agonist

MedKoo Cat#: 328106 | Name: Suriclone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Suriclone, also known as RP-31264, is an anxiolytic drug belonging to the family of cyclopyrrolones. Suriclone has a very similar pharmacological profile to the benzodiazepine family of drugs including sedative and anxiolytic properties but with less amnestic effects. The mechanism of action by which suriclone produces its sedative and anxiolytic effects is by modulating GABA-A receptors, although suriclone is more subtype-selective than most benzodiazepines.

Chemical Structure

Suriclone

CAS#53813-83-5

Theoretical Analysis

MedKoo Cat#: 328106

Name: Suriclone

CAS#: 53813-83-5

Chemical Formula: C20H20ClN5O3S2

Exact Mass: 477.0696

Molecular Weight: 477.98

Elemental Analysis: C, 50.26; H, 4.22; Cl, 7.42; N, 14.65; O, 10.04; S, 13.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Suriclone; RP 31264; RP-31264; RP31264

IUPAC/Chemical Name

6-(7-chloro-1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-5H-[1,4]dithiino[2,3-c]pyrrol-5-yl 4-methylpiperazine-1-carboxylate

InChi Key

RMXOUBDDDQUBKD-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3

SMILES Code

O=C(N1CCN(C)CC1)OC(C2=C3SCCS2)N(C4=NC5=NC(Cl)=CC=C5C=C4)C3=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 477.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Morishita H, Kushiku K, Matsuki J, Tokunaga T, Inoue T, Mori R, Kawamoto H, Furukawa T. Pharmacological effects of the antianxiety compound suriclone and its principal metabolites. Arzneimittelforschung. 1987 Dec;37(12):1332-40. PubMed PMID: 2896505. 2: Ono H, Morishita S, Kasuya M, Kobayashi M, Miyamoto M, Oka J, Goto M, Fukuda H. Comparison of the effects of the new anxiolytic suriclone and benzodiazepines on motor function and electroencephalogram. Arzneimittelforschung. 1987 Apr;37(4):384-8. PubMed PMID: 2886128. 3: Semlitsch HV, Anderer P, Saletu B. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Eur J Clin Pharmacol. 1995;49(3):183-91. PubMed PMID: 8665994. 4: Perault MC, Chapelle G, Bouquet S, Chevalier P, Montay G, Gaillot J, Chakroun H, Guillet P, Vandel B. Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man. Fundam Clin Pharmacol. 1994;8(3):251-5. PubMed PMID: 7927120. 5: Brouillet E, Chavoix C, Hantraye P, Kunimoto M, Khalili-Varasteh M, Chevalier P, Frydman A, Gaillot J, Prenant C, Crouzel M, et al. Interaction of suriclone with central type benzodiazepine receptors in living baboons. Eur J Pharmacol. 1990 Jan 3;175(1):49-55. PubMed PMID: 1969798. 6: Shaw CA, Sellers EM, Sullivan JT, Kaplan HL. Comparative neurologic effects of diazepam and suriclone, a cyclopyrrolone anxiolytic. J Clin Psychopharmacol. 1988 Jun;8(3):189-92. PubMed PMID: 2897978. 7: Saletu B, Grünberger J, Linzmayer L, Semlitsch HV, Anderer P, Chwatal K. Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry. Br J Clin Pharmacol. 1994 Feb;37(2):145-56. PubMed PMID: 7910470; PubMed Central PMCID: PMC1364591. 8: Gilburt SJ, Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of suriclone on subjective sleep, psychomotor performance and cognitive function in young and elderly volunteers. Fundam Clin Pharmacol. 1992;6(6):251-8. PubMed PMID: 1362556. 9: Allen D, Lader M. The interactions of ethanol with single and repeated doses of suriclone and diazepam on physiological and psychomotor functions in normal subjects. Eur J Clin Pharmacol. 1992;42(5):499-505. PubMed PMID: 1351467. 10: Trifiletti RR, Snyder SH. Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol. 1984 Nov;26(3):458-69. PubMed PMID: 6092896.